Evidence of reactive astrocytes but not peripheral immune system activation in a mouse model of Fragile X syndrome.

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Biochimica et Biophysica Acta

• Publication date

  2010-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.bbadis.2010.06.015PMID 20600866PMCID PMC2942952
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Innate and adaptive immune responses regulated by glycogen synthase kinase-3 (GSK3).

  2010influential reference
• Plasma cytokine profiles in Fragile X subjects: is there a role for cytokines in the pathogenesis?

  2010cited by this paper
• Lithium ameliorates altered glycogen synthase kinase-3 and behavior in a mouse model of fragile X syndrome.

  2010influential reference
• Astrocytes Prevent Abnormal Neuronal Development in the Fragile X Mouse

  2010cited by this paper
• GSK3 Influences Social Preference and Anxiety-Related Behaviors during Social Interaction in a Mouse Model of Fragile X Syndrome and Autism

  2010cited by this paper
• Immune involvement in schizophrenia and autism: etiology, pathology and animal models.

  2009cited by this paper
• Lipopolysaccharide-induced interleukin-6 production is controlled by glycogen synthase kinase-3 and STAT3 in the brain

  2009cited by this paper
• Unique and Overlapping Functions of GSK-3 Isoforms in Cell Differentiation and Proliferation and Cardiovascular Development*

  2009cited by this paper
• Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

  2009influential reference
• Glycogen synthase kinase-3 regulates microglial migration, inflammation, and inflammation-induced neurotoxicity.

  2009cited by this paper
• Dissociation of social and nonsocial anxiety in a mouse model of fragile X syndrome.

  2009cited by this paper
• Innate immunity and neuroinflammation in the CNS: The role of microglia in Toll‐like receptor‐mediated neuronal injury

  2009cited by this paper
• Social approach in genetically engineered mouse lines relevant to autism

  2009cited by this paper
• Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression.

  2009cited by this paper
• Social behavior in Fmr1 knockout mice carrying a human FMR1 transgene.

  2008cited by this paper
• Differential Regulation of STAT Family Members by Glycogen Synthase Kinase-3*

  2008cited by this paper
• Advances in behavioral genetics: mouse models of autism

  2008cited by this paper
• Glial fibrillary acidic protein is elevated in superior frontal, parietal and cerebellar cortices of autistic subjects

  2008cited by this paper
• Open-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome

  2008cited by this paper
• Evidence for social anxiety and impaired social cognition in a mouse model of fragile X syndrome.

  2008cited by this paper
• Immune transcriptome alterations in the temporal cortex of subjects with autism.

  2008cited by this paper
• Neuroinflammation and synaptic plasticity: theoretical basis for a novel, immune-centred, therapeutic approach to neurological disorders.

  2008cited by this paper
• Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model

  2008cited by this paper
• Fragile x mental retardation (Fmr-1) gene expression is down regulated in brain of mice during aging

  2007cited by this paper
• Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X.

  2007cited by this paper
• Correction of fragile X syndrome in mice.

  2007cited by this paper
• Developmental expression of FMRP in the astrocyte lineage: Implications for fragile X syndrome

  2007cited by this paper
• Glycogen Synthase Kinase-3 (GSK3): Inflammation, Diseases, and Therapeutics

  2007cited by this paper
• Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome.

  2007cited by this paper
• The immune response in autism: a new frontier for autism research

  2006cited by this paper
• ADHD symptoms in children with FXS

  2006cited by this paper
• Fragile X syndrome and autism at the intersection of genetic and neural networks

  2006cited by this paper
• Autistic behavior in children with fragile X syndrome: Prevalence, stability, and the impact of FMRP

  2006cited by this paper
• Social behavior deficits in the Fmr1 mutant mouse.

  2006cited by this paper
• Altered anxiety‐related and social behaviors in the Fmr1 knockout mouse model of fragile X syndrome

  2005cited by this paper
• Neuroglial activation and neuroinflammation in the brain of patients with autism

  2005cited by this paper
• Immunity, neuroglia and neuroinflammation in autism

  2005cited by this paper
• Recent advances in fragile X: a model for autism and neurodegeneration

  2005cited by this paper
• Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome.

  2005cited by this paper
• Toll-like receptor–mediated cytokine production is differentially regulated by glycogen synthase kinase 3

  2005cited by this paper
• Plasticity of nonneuronal brain tissue: roles in developmental disorders.

  2004cited by this paper
• The mGluR theory of fragile X mental retardation.

  2004cited by this paper
• Social behavior profile in young males with fragile X syndrome: Characteristics and specificity

  2004cited by this paper
• The glamour and gloom of glycogen synthase kinase-3.

  2004cited by this paper
• GFAP: Functional implications gleaned from studies of genetically engineered mice

  2003cited by this paper
• GSK-3: tricks of the trade for a multi-tasking kinase

  2003cited by this paper
• Immunity

  2003cited by this paper
• Glycogen synthase kinase-3beta: a novel regulator of cardiac hypertrophy and development.

  2002cited by this paper
• Expression of glycogen synthase kinase-3 isoforms in mouse tissues and their transcription in the brain.

  2002cited by this paper
• Behavioral and neuroanatomical characterization of the Fmr1 knockout mouse

  2002cited by this paper
• GSK3 takes centre stage more than 20 years after its discovery.

  2001cited by this paper
• Anti-bipolar therapy: mechanism of action of lithium

  1999cited by this paper
• Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells.

  1996cited by this paper
• A molecular mechanism for the effect of lithium on development.

  1996cited by this paper
• Fmr1 knockout mice: a model to study fragile X mental retardation. The Dutch-Belgian Fragile X Consortium.

  1994cited by this paper
• FMR1 Knockout mice: A model to study fragile X mental retardation

  1994cited by this paper
• Molecular cloning and expression of glycogen synthase kinase‐3/factor A.

  1990cited by this paper

• Hippocampal glial alterations are associated with Lamin B1 dysregulation and abnormal nuclear morphology in a rat model of fragile X syndrome.

  2026cites this paper
• Lack of FMRP in the retina: evidence of a retinal specific transcriptomic profile.

  2024cites this paper
• An experimentally validated approach to automated biological evidence generation in drug discovery using knowledge graphs

  2024cites this paper
• Scheduled feeding improves behavioral outcomes and reduces inflammation in a mouse model of Fragile X syndrome

  2024cites this paper
• From synapses to circuits: What mouse models have taught us about how autism spectrum disorder impacts hippocampal function.

  2024cites this paper
• Astrocytes in fragile X syndrome

  2024cites this paper
• Role of Fragile X Messenger Ribonucleoprotein 1 in the pathophysiology of brain disorders: a glia perspective.

  2024influential citation
• Hippocampal Upregulation of Complement Component C3 in Response to Lipopolysaccharide Stimuli in a Model of Fragile-X Syndrome

  2023cites this paper
• Glial-mediated dysregulation of neurodevelopment in Fragile X Syndrome.

  2023cites this paper
• Astrocyte: A Foe or a Friend in Intellectual Disability-Related Diseases

  2022cites this paper
• FMRP-related retinal phenotypes: Evidence of glutamate-glutamine metabolic cycle impairment.

  2022cites this paper
• Aberrant astrocyte protein secretion contributes to altered neuronal development in multiple models of neurodevelopmental disorders

  2022cites this paper
• Converging purinergic and immune signaling pathways drive IL-6 secretion by Fragile X cortical astrocytes via STAT3.

  2021cites this paper
• Deciphering the roles of glycogen synthase kinase 3 (GSK3) in the treatment of autism spectrum disorder and related syndromes

  2021cites this paper
• Astrocyte-mediated disruption of ROS homeostasis in Fragile X mouse model.

  2021cites this paper
• Rethinking Intellectual Disability from Neuro- to Astro-Pathology

  2020cites this paper
• Healing autism spectrum disorder with cannabinoids: a neuroinflammatory story.

  2020cites this paper
• Aberrant astrocyte protein secretion contributes to altered neuronal development in diverse disorders

  2020cites this paper
• Repurposing Fragile X Drugs to Inhibit SARS-CoV-2 Viral Reproduction

  2020cites this paper
• Altered cortical Cytoarchitecture in the Fmr1 knockout mouse

  2019cites this paper
• Reduced serum levels of pro-inflammatory chemokines in fragile X syndrome

  2019cites this paper
• Molecular Biomarkers in Fragile X Syndrome

  2019cites this paper
• Lipopolysaccharide-induced inflammation leads to acute elevations in pro-inflammatory cytokine expression in a mouse model of Fragile X syndrome.

  2019cites this paper
• Do Astrocytes Play a Role in Intellectual Disabilities?

  2019cites this paper
• Astrocytes are direct cellular targets of lithium treatment: novel roles for lysyl oxidase and peroxisome-proliferator activated receptor-γ as astroglial targets of lithium

  2019cites this paper
• Regulation of IL-6 Secretion by Astrocytes via TLR4 in the Fragile X Mouse Model

  2018cites this paper
• IL-6 SECRETION BY ASTROCYTES IN FRAGILE X MICE ACTIVATION OF TLR4 BY TENASCIN C THROUGH THE INDUCTION OF INTERLEUKIN-6 IN THE FRAGILE X MOUSE MODEL

  2018cites this paper
• Neuroglia in the autistic brain: evidence from a preclinical model

  2018cites this paper
• Glycogen Synthase Kinase-3: Abnormalities and Therapeutic Potential in Fragile X Syndrome

  2017cites this paper
• Drug Discovery for Targeted Pharmacotherapy of Fragile X Syndrome

  2017cites this paper
• Adult Fmr1 knockout mice present with deficiencies in hippocampal interleukin-6 and tumor necrosis factor-&agr; expression

  2017cites this paper
• Expression of mutant DISC1 in Purkinje cells increases their spontaneous activity and impairs cognitive and social behaviors in mice.

  2017cites this paper
• Light and electronic histological studies to the effect of Sofosbuvir on the visual cerebral cortex of adult male albino rat

  2017cites this paper
• Astrocytes as new targets to improve cognitive functions.

  2016cites this paper
• Neuro-Inflammatory Mechanisms in Developmental Disorders Associated with Intellectual Disability and Autism Spectrum Disorder: A Neuro- Immune Perspective.

  2016cites this paper
• Protease induced plasticity: matrix metalloproteinase-1 promotes neurostructural changes through activation of protease activated receptor 1

  2016cites this paper
• Astrocytes and Microglia and Their Potential Link with Autism Spectrum Disorders

  2016cites this paper
• Imbalance between Glutamate and GABA in Fmr1 Knockout Astrocytes Influences Neuronal Development

  2016cites this paper
• Sex differences in neurodevelopmental and neurodegenerative disorders: Focus on microglial function and neuroinflammation during development.

  2016cites this paper
• Virus-mediated Delivery of the Fmr1 Gene as a Tool for the Treatment of Fragile X Syndrome

  2016cites this paper
• The MMP-1/PAR-1 Axis Enhances Proliferation and Neuronal Differentiation of Adult Hippocampal Neural Progenitor Cells

  2015cites this paper
• Expression of fragile X mental retardation protein in neurons and glia of the developing and adult mouse brain.

  2015cites this paper
• Award Number: W81XWH-12-1-0596 TITLE: Examination of the mGluR-mTOR Pathway for the Identification of Potential Therapeutic Targets To Treat Fragile X

  2015cites this paper
• Therapeutic approaches for the future treatment of Fragile X

  2015cites this paper
• Dendritic spine abnormalities in a mouse model of Fragile X syndrome

  2015cites this paper
• Gene expression analysis in Fmr1KO mice identifies an immunological signature in brain tissue and mGluR5-related signaling in primary neuronal cultures

  2015cites this paper
• Treatment of Fragile X Syndrome with a Neuroactive Steroid

  2015cites this paper
• Pathological Plasticity and Glutamate Transport in Fragile-X Tremore and Ataxia Syndrome

  2015cites this paper
• Aberrant microRNA expression in spinal muscular atrophy motor neurons

  2015cites this paper
• Epilepsy and innate immune system: A possible immunogenic predisposition and related therapeutic implications

  2015cites this paper
• The Role of the Immune System in Triplet Repeat Expansion Diseases

  2015cites this paper
• Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises

  2015cites this paper
• Persistent astrocyte activation in the fragile X mouse cerebellum

  2015cites this paper
• PDE-4 Inhibition Rescues Aberrant Synaptic Plasticity in Drosophila and Mouse Models of Fragile X Syndrome

  2015cites this paper
• Analysis of Fmr1 Deletion in a Subpopulation of Post‐Mitotic Neurons in Mouse Cortex and Hippocampus

  2014cites this paper
• Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule

  2014cites this paper
• Effects of lithium on inflammation.

  2014cites this paper
• Intestinal inflammation in a murine model of autism spectrum disorders.

  2014cites this paper
• Altered glial marker expression in autistic post-mortem prefrontal cortex and cerebellum

  2014cites this paper
• Pre-clinical models of neurodevelopmental disorders: focus on the cerebellum

  2014cites this paper
• Autism spectrum disorders: neurotrophins enter the dance

  2014cites this paper
• Divergent dysregulation of gene expression in murine models of fragile X syndrome and tuberous sclerosis

  2014cites this paper
• Dietary supplementation of omega-3 fatty acids rescues fragile X phenotypes in Fmr1-Ko mice.

  2014cites this paper
• Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.

  2014cites this paper
• Group I metabotropic glutamate receptor mediated dynamic immune dysfunction in children with fragile X syndrome

  2014cites this paper
• Lithium treatment alleviates impaired cognition in a mouse model of fragile X syndrome

  2013influential citation
• Epilepsy in four genetically determined syndromes of intellectual disability.

  2013cites this paper
• TITLE: Examination of the mGluR-mTOR Pathway for the Identification of Potential Therapeutic Targets to Treat Fragile X. PRINCIPAL INVESTIGATOR:

  2013cites this paper
• The role of beta-adrenergic receptor blockers in autism

  2013cites this paper
• Enhanced Asynchronous Ca2+ Oscillations Associated with Impaired Glutamate Transport in Cortical Astrocytes Expressing Fmr1 Gene Premutation Expansion*

  2013cites this paper
• The Role of Thiamine in Autism

  2013cites this paper
• Review Article The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome

  2012cites this paper
• Pathways to Drug Development for Autism Spectrum Disorders

  2012cites this paper
• Fragile X syndrome and targeted treatment trials.

  2012cites this paper
• Excessive Astrocyte-Derived Neurotrophin-3 Contributes to the Abnormal Neuronal Dendritic Development in a Mouse Model of Fragile X Syndrome

  2012cites this paper
• The role of glycogen synthase kinase-3 signaling in neurodevelopment and fragile X syndrome.

  2012cites this paper
• Glycogen Synthase Kinase-3: A Promising Therapeutic Target for Fragile X Syndrome

  2011influential citation
• Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study

  2011cites this paper
• Causes of learning disability and epilepsy: a review.

  2011cites this paper
• Pathways underlying the gut-to-brain connection in autism spectrum disorders as future targets for disease management.

  2011cites this paper
• The neurochemical basis for the treatment of autism spectrum disorders and Fragile X Syndrome.

  2011cites this paper
• “For Whom the Bell Tolls”: Blockade of Toll-Like Receptors May Regulate Seizure Occurrence

  2010cites this paper
• How Does Altered Metabolism Lead to Seizure Control? Partially Filling the Knowledge Gap

  2010cites this paper
• Neurosteroids on the Epilepsy Chessboard—Keeping Seizures in Check

  2010cites this paper